✓ 1Q 2024 marks 15th consecutive quarter of >15% YOY royalty growth • Ocrelizumab SC (EU), mid-2024 ≫ | --- | --- | --- | |--------------------------|--------------|------------| | 1Q 2024 Phesgo ® Sales | Sales (CHFm) | Growth CER | | TOTAL | 338 | 70% | | US | 126 | 36% | | EU | 169 | 55% | | Japan | 19 | NA | | International | 74 | 165% | 8 2 Product Approvals Total DARZALEX® Sales IV+SC ($B) 1 85% of patients preferred Phesgo® for subcutaneous administration over the intravenous formulation of Perjeta a ...